SWOG clinical trial number
CTSU/E1105

A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer

Closed
Phase
Abbreviated Title
ADVANCED: Phase III Chemo and Trastuzumab +/- Bevacizumab for HER-2/neu Metastatic Breast Cancer
Activated
12/01/2007
Closed
10/28/2009
Participants
CTSU

Research committees

Breast Cancer

Treatment

Trastuzumab Bevacizumab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2024

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu over-expressing metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

J Mezzanotte-Sharpe;A O'Neill;I Mayer;C Arteaga;X Yang;L Wagner;D Celia;N Meropol;R Alpaugh;T Saphner;R Swaney;K Hoelzer;W Gradishar;V Abramson;K Sundaram;S Jilani;E Perez;N Lin;M Jahanzeb;G Sledge;S Reid Breast Cancer Research and Treatment Sep;207(2):275-282

PMid: PMID38967884 | PMC number: PMC11297090

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
21%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
31%
Open
Phase